TIVDAK

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Colorectal NeoplasmsVulvar Carcinoma

23 competitors in Colorectal Neoplasms

#DrugCompanyPhaseTrials

1

Avastin

Roche

Phase 3

52

Eloxatin

Teva

Phase 3

43

Camptosar

Pfizer

Phase 3

24

Rybrevant

Johnson & Johnson

Phase 3

25

Camptosar

Pfizer

Phase 3

16

Tukysa

Pfizer

Phase 3

17

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 3

28

Herceptin

OOrganon and Co

Phase 3

19

Fusilev

AActavis Inc.

Phase 3

110

Adrucil

EElorac, Inc.

Phase 3

1Show 12 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Cervical Cancer4 trials

A Trial of Tisotumab Vedotin in Cervical Cancer

Completed·Pfizer·Phase 2·NCT03438396·102 enrolled

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Completed·Pfizer·Phase 3·NCT04697628·502 enrolled

A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)

Active, not recruiting·Merck & Co.·Phase 3·NCT06459180·686 enrolled

Show 1 more trial

A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer

Terminated·Pfizer·Preclinical·NCT03786081·214 enrolled

Patients With Solid Tumors3 trials

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Completed·Pfizer·Phase 1/2·NCT02001623·195 enrolled

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Completed·Pfizer·Phase 2·NCT03245736·5 enrolled

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Completed·Pfizer·Phase 1/2·NCT02552121·33 enrolled

Solid Malignancies1 trial

To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies

Completed·ZZai Lab (Shanghai) Co., Ltd.·Phase 1·NCT05866354·19 enrolled

Ovarian Cancer1 trial

A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

Completed·Pfizer·Phase 2·NCT03657043·98 enrolled

Advanced Solid Malignancies1 trial

A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies

Completed·Genmab·Phase 1/2·NCT03913741·23 enrolled

2 more indications

Colorectal Neoplasms1 trial

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

Active, not recruiting·Pfizer·Phase 2·NCT03485209·350 enrolled

Vulvar Carcinoma1 trial

Phase II Study Tisotumab Vedotin in Metastatic or Recurrent Squamous Cell Carcinoma of the Vulva

Not yet recruiting·GGOG Foundation·Phase 2·NCT07672782·28 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News